Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
Latest Information Update: 01 Aug 2021
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms PRIME
- Sponsors Dendreon Corporation
- 24 Jul 2021 Results of assessing the analysis of circulating immune biomarkers among racial subgroups of Black and white men with metastatic castration-resistant prostate cancer treated with sipuleucel-t, published in the Journal of the National Cancer Institute.
- 04 Jun 2019 Results assessing antigen (Ag) spread and overall survival in real-world patients from this study, were presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jul 2017 Status changed from recruiting to discontinued due to Completion of 3yr follow up.